coramaze technologies is a Munich-based medical device company founded in 2013 by CEO Laura Figulla that is developing the mitramaze® valve repair system. The mitramaze system is a novel transcatheter mitral valve repair (TMVRep) concept intended to treat inoperable patients with severe functional mitral regurgitation (fMR). fMR prevents the mitral valve from sealing due to left ventricular enlargement, causing dyspnea, impaired exercise tolerance and increased mortality; many patients are excluded from surgical options. coramaze closed a €4.5m (US$5.15m) Series A to advance its implant design toward clinical testing. Proceeds will fund a first-in-human clinical investigational study in 2016 and a subsequent feasibility trial to support European CE approval. coramaze technologies GmbH is developing the mitramaze® valve repair system for minimally invasive treatment of mitral regurgitation. The company is advancing a device designed for atraumatic insertion and stable intraventricular positioning, and the technology may also be applicable to tricuspid regurgitation and other structural heart valve diseases. coramaze plans to use the newly raised funds to advance pre-clinical development of mitramaze® for patient segments that cannot undergo standard cardiac surgery. Founded in 2013 as a spin‑off from the Western German Heart Center, the company is led by CEO Dr. Laura Figulla and Prof. Dr. Till Neumann and is based in Essen, Germany. The mitramaze® technology was developed through a research project funded by the German Federal Ministry of Economics and Technology’s EXIST research transfer program. Financially, coramaze raised €1m in the reported funding round.

Total raised

$6M

Funding rounds

2

Latest round

Series A

Latest activity

Sep 2015